The implantable cardiac defibrillator (ICD) market may be poised to rebound from the black eye it has suffered following recalls and recent lead malfunctions, based on news from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) trial - intended to establish that patients with mild heart failure may benefit from cardiac resynchronization therapy (CRT).

REVERSE data still likely to boost ICD market prospects

Name: Relias Media
Price range: $

January 2, 2015

Reprints

Recognizing, Managing, and Reporting Pediatric Sexual Abuse and Assault
Eleventh Circuit Affirms Jury Verdict of $2.5 Million for Mesh Device Plaintiff Despite Close Call on Statute of Limitations
Indiana Appellate Court Allows Case to Proceed Against Doctor Accused of Improperly Accessing Patients’ Medical Records
Malpractice Insurance Rates Increasing After Stable Period
Clinical Decision Software Highly Effective in OR